Building a Brighter future for drug discovery
Please join us for a seminar with guest speaker Professor Trevor Perrior, Domainex Ltd
How can we invent better drugs faster? This is one of the major challenges facing the pharma and biotech industries, and Domainex has responded by focusing on the efficiency of its drug hunting approach. The emphasis on maximum efficiency shapes Domainex’s strategic technologies, and also the tactics that are used by its highly-experienced medicinal chemists and biologists to find hit compounds and rapidly optimise them into drug candidates. Trevor will describe some aspects of the Domainex approach and illustrate these with some recent drug research programmes at Domainex.
About the speaker:
Trevor studied and undertook academic research at Cambridge, Oxford, and in the USA before beginning his industrial career as a Team Leader with ICI in 1984. He held a number of R&D roles within the bioscience businesses of ICI, Zeneca and AstraZeneca. This culminated in his appointment as Global Head of Chemistry for the agrochemicals business, where he led a department of 150 chemists across several sites in the UK, USA, and Switzerland.
Trevor then joined Celltech’s pharmaceutical business where he became Director of NCE Research and Head of Chemistry, with responsibility for leading the small-molecule research programs against inflammation and oncology targets, and for the line management of a team of 100 medicinal and process chemists.
In 2005 Trevor joined NCE Discovery - a Contract Research Organisation – as its Chief Scientific Officer, and this company merged with Domainex a year later.
Trevor has led teams that have delivered fourteen development candidates across several therapeutic areas. He has experience of working in both ‘big pharma’, ‘biotech’, and CRO companies; expertise in research on GPCR, kinase, ion-channel, and general enzyme drug targets; and in pre-clinical development. He is an inventor on over 50 patents, and an author of over 20 scientific papers and articles. In 2005 he was elected a Fellow of the Royal Society of Chemistry, and he is the Visiting Professor of Medicinal Chemistry at the University of Sussex.
A light lunch and networking will follow the seminar.
One-on-ones will be available for half an hour starting from 2.00pm
